Sensus Healthcare makes superficial radiation therapy (SRT) devices for nonmelanoma skin cancer. One product. One company. No public competitors. $65M market cap. Zero real analyst coverage.

On January 1, 2026, CMS awarded SRTS exclusive dedicated CPT codes for SRT/IGSRT — ending a 16-year lobbying effort. This removes the single biggest barrier to physician adoption: clear, unambiguous Medicare reimbursement for a $300K+ capital device. The 10-K filed March 4 confirms the setup and reveals both bullish mechanics the market hasn't modeled and bearish risks it hasn't priced.

The Thesis

New CPT codes change physician economics overnight. Reimbursement clarity drives diversified adoption across dermatology practices. R&D normalizes after one-time lobbying costs. The FDA lease program auto-lifts on higher rates. A company that just lost $7.7M returns to profitability in 2026.

What the 10-K Shows

FY2025 was ugly by design. Revenue $27.5M vs $41.8M (-34%). Net loss $7.7M vs net income $6.6M. Units sold: 70 vs 115. Gross margins collapsed from 58.4% to 43.3%.

But the filing tells you why. The 10-K explicitly states that the July 2025 CPT code proposal "significantly impacted 2025 sales numbers for the Company, as customers anticipated use of the new codes in 2026." Customers stopped buying. They were waiting for January 1. This is pent-up demand, confirmed in the legally binding document, not management spin on an earnings call.

Meanwhile, management spent the transition year building:

• Inventory: $14.6M, up 44% YoY. They pre-built ≈120 units. You don't stockpile $4.5M in extra inventory unless you expect to ship it.
• Sales infrastructure: S&M up 30% to $6.5M. Hired reps for the wave.
• Commercial programs: Sensus Healthcare Financial Services (bank financing for device purchases) and Sensus Link (cloud software extending Vision-class features to base SRT-100). Both launched February 2026.
• Second supplier: Added Koplak LLC alongside primary manufacturer RbM for "ramping up inventory more quickly in the event of significantly increased demand."

This is a company preparing for an inflection, not one in distress. The $7.7M loss is an investment: $3-4M in one-time CPT lobbying costs (now over), plus commercial infrastructure buildout.

The Sleeper: FDA Lease Pass-Through

Buried in Note 5 of the 10-K is the most underappreciated mechanic.

The Fair Deal Agreement (FDA) program places SRT devices in practices on 60-month leases. Revenue splits into fixed payments ($256K in 2025) and variable payments tied to reimbursement collected ($1.465M in 2025). Variable payments were 87% of 2025 FDA program revenue and grew from $55K to $1.465M — 27x year-over-year.

Here's the point: new higher CPT reimbursement rates effective January 1, 2026 immediately increase variable payments on ALL existing 60-month leases. No new sales required. No new customer acquisition. The 18 active sites (plus 10 in activation) generate more revenue automatically because the per-treatment reimbursement is higher.

Nobody reads Note 5 on a $65M stock with zero coverage. This is where the first evidence of CPT code impact will show up — before it appears in new unit sales.

The Bear Case (Real, Not Dismissable)

Customer concentration. One unnamed U.S. customer was 52% of FY2025 revenue (≈$14.3M) and 65% of receivables. Down from 73% of 2024 revenue, but still enormous. Management's 2026 model explicitly excludes this customer. They need to roughly DOUBLE their diversified customer revenue to reach profitability. That's aggressive for a company that's never done it before.

DOJ investigation. A Civil Investigative Demand has been open since August 2019 — 6.4 years — investigating Medicare billing by a physician using SRTS SRT-100. It expanded to include whether the company was involved in reimbursement code issues. No determination. Cost "unable to estimate." Now that SRTS has new exclusive CPT codes and expects Medicare billing to surge, DOJ scrutiny of billing practices could intensify. This is an unsizable tail risk on a $65M company.

Covenant default. The company is in technical default on its Comerica $15M credit facility for failing the minimum profitability covenant. Zero drawn, $22M cash — no immediate cash risk. But Comerica was acquired by Fifth Third in February 2026. New bank, new relationship, uncertain outcome. Buried in Note 3.

Mix shift. The 10-K adds a new warning not in the Q4 earnings call: "decreased demand for its higher priced SRT device." If physicians buy the base SRT-100 instead of the Vision/Plus, gross margins stay at 43% even with volume recovery. Breakeven revenue at 43% margins is $42-44M. At 50% margins, it's $36-38M. The margin question determines whether profitability is achievable at realistic revenue levels.

Management tone divergence. The Q4 earnings call was confident — CEO called the CPT codes the end of "16 years of relentless pursuit." The 10-K MD&A lists four specific headwinds and says the company "faces a number of uncertainties in 2026 that could impact our ability to achieve this goal." The legally binding document is more cautious than the verbal guidance.

Factor Decomposition

Edge-weighted variance: ≈80%. The only material factor where we're completely blind is DOJ (10%). Everything else is either our edge zone (CPT mechanics, FDA pass-through that nobody reads) or simple math nobody's doing (R&D normalization).

Market-Implied vs Our View

Current price $4.44 on a $73M market cap. Cash is $22.1M. Enterprise value ≈$51M for a business that lost $7.7M.

Back out the implied probabilities:

The gap is on the bull case: 24 percentage points. Market gives 6% probability to full CPT adoption success. We give 30%.

Why the market might be wrong: zero analyst coverage means nobody is modeling the CPT mechanics. The FDA lease pass-through is in Note 5. R&D normalization is arithmetic nobody's doing. And 8 open-market insider purchases across 3 insiders over 7 months — CEO ($100K at $4.03), President, Director ($3.81 as recently as February 24) — is a signal that doesn't register on any institutional scanner for a $73M name with 93 total options OI.

Why the market might be right: single-product micro-caps fail all the time. 52% customer concentration going to zero is genuinely unproven. DOJ could file suit. And maybe the premium device really is dead.

Forward Alpha

EV = (0.30 x $10) + (0.40 x $5.50) + (0.30 x $2.50) = $5.95
Return from $4.44 = +34% / 18 months = ≈22% annualized
Excess over IHI (≈8%): ≈14%
Edge%: ≈85%
Alpha: ≈12% annualized

Entry matters. Alpha nearly triples at $3.50 vs $4.44. Optimal zone is $3.50-4.13 (200-day MA). Above $5.00, R/R to a reasonable stop compresses significantly.

The Critical Gap

The actual CMS reimbursement rates for the new CPT codes are not in the 10-K. This is the single most important number in the entire thesis. Per-fraction rate times a typical 20-30 fraction course equals physician revenue per patient. That number, compared to the $300K+ device cost, determines whether physician ROI makes adoption inevitable or marginal.

Everything else — pent-up demand, FDA pass-through, R&D normalization, commercial infrastructure — is scaffolding around this one unknown.

Conclusion

SRTS is a monopoly product at a micro-cap market cap with an irreversible regulatory catalyst that landed 10 weeks ago, insider buying with real money, zero institutional coverage, and a mechanical pass-through in the footnotes that nobody's modeling.

The 10-K confirms the bull case mechanics. It also surfaces two risks the market hasn't priced: a covenant default buried in Note 3 and a 6-year DOJ investigation that gains relevance as billing volumes surge. The MD&A is more cautious than the earnings call, and the mix shift warning on premium devices is new.

Net: mildly bullish. The alpha is ≈12% annualized from current levels — legitimate but not screaming. The shape is what matters: asymmetric upside if Q1 confirms diversification, limited downside to a $22M cash floor at 1% sizing. Q1 earnings May 14 is the first hard test.

If the pent-up demand shows up in diversified revenue — not concentrated in the excluded customer — this re-rates fast on a name with nobody in the way.

Evidence